{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:15:47Z","timestamp":1791314147813,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Diagnostic needle biopsies that miss clinically significant prostate cancer (PCa) often sample benign tissue near hidden cancers. Such benign samples might still display subtle morphological signs of cancer elsewhere in the prostate. This study examined if artificial intelligence (AI) could detect these morphological clues in benign biopsies from men with elevated prostate-specific antigen (PSA) levels to predict subsequent diagnosis of clinically significant PCa within 30 months. We analysed biopsies from 232 men initially diagnosed as benign, matched for age, diagnosis year, and PSA levels-half were later diagnosed with PCa, while the rest remained cancer-free for at least eight years. The AI model accurately predicted future PCa diagnosis from initial benign biopsies (AUC = 0.82), highlighting patterns such as changes in stromal collagen and altered glandular epithelial cells. This demonstrates that AI analysis of routine haematoxylin-eosin biopsy sections can detect subtle signs indicating clinically significant PCa before it becomes histologically apparent. Such morphological patterns shed light on the broader tissue alterations induced by prostate cancer, even in benign tissue, potentially enhancing early detection and clinical decision-making.<\/jats:p>","DOI":"10.1038\/s41598-025-15105-6","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T13:53:44Z","timestamp":1755784424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Discovery of tumour indicating morphological changes in benign prostate biopsies through AI"],"prefix":"10.1038","volume":"15","author":[{"given":"Eduard","family":"Chelebian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Avenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"J\u00e4remo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"W\u00e4hlby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"15105_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"15105_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10, 63 (2019).","journal-title":"World J. Oncol."},{"key":"15105_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","volume":"53","author":"A Heidenreich","year":"2008","unstructured":"Heidenreich, A. et al. Eau guidelines on prostate cancer. Eur. Urol. 53, 68\u201380 (2008).","journal-title":"Eur. Urol."},{"key":"15105_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2006.03.026","volume":"50","author":"J Walz","year":"2006","unstructured":"Walz, J. et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur. Urol. 50, 498\u2013505 (2006).","journal-title":"Eur. Urol."},{"key":"15105_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","volume":"175","author":"K Eichler","year":"2006","unstructured":"Eichler, K. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J. Urol. 175, 1605\u20131612 (2006).","journal-title":"J. Urol."},{"key":"15105_CR6","first-page":"262","volume":"10","author":"SF Shariat","year":"2008","unstructured":"Shariat, S. F. & Roehrborn, C. G. Using biopsy to detect prostate cancer. Rev. Urol. 10, 262 (2008).","journal-title":"Rev. Urol."},{"key":"15105_CR7","doi-asserted-by":"publisher","first-page":"E293","DOI":"10.5489\/cuaj.1248","volume":"7","author":"EC Serefoglu","year":"2013","unstructured":"Serefoglu, E. C. et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer?. Can. Urol. Assoc. J. 7, E293 (2013).","journal-title":"Can. Urol. Assoc. J."},{"key":"15105_CR8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/pros.20983","volume":"69","author":"L Nonn","year":"2009","unstructured":"Nonn, L., Ananthanarayanan, V. & Gann, P. H. Evidence for field cancerization of the prostate. Prostate 69, 1470\u20131479 (2009).","journal-title":"Prostate"},{"key":"15105_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1517\/17530059.2011.540009","volume":"5","author":"S Halin","year":"2011","unstructured":"Halin, S., Hammarsten, P., Adamo, H., Wikstr\u00f6m, P. & Bergh, A. Tumor indicating normal tissue could be a new source of diagnostic and prognostic markers for prostate cancer. Expert Opinion Med. Diagnostics 5, 37\u201347 (2011).","journal-title":"Expert Opinion Med. Diagnostics"},{"key":"15105_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41467-017-01027-z","volume":"8","author":"D Aran","year":"2017","unstructured":"Aran, D. et al. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat. Commun. 8, 1077 (2017).","journal-title":"Nat. Commun."},{"key":"15105_CR11","doi-asserted-by":"crossref","unstructured":"Slaughter, D.\u00a0P., Southwick, H.\u00a0W. & Smejkal, W. \u201cfield cancerization\u201d in oral stratified squamous epithelium. clinical implications of multicentric origin. Cancer. 6, 963\u2013968 (1953).","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q"},{"key":"15105_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141601","volume":"10","author":"HH Adamo","year":"2015","unstructured":"Adamo, H. H., Str\u00f6mvall, K., Nilsson, M., Halin Bergstr\u00f6m, S. & Bergh, A. Adaptive (tint) changes in the tumor bearing organ are related to prostate tumor size and aggressiveness. PLoS One 10, e0141601 (2015).","journal-title":"PLoS One"},{"key":"15105_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130076","volume":"10","author":"HH Adamo","year":"2015","unstructured":"Adamo, H. H., Halin Bergstr\u00f6m, S. & Bergh, A. Characterization of a gene expression signature in normal rat prostate tissue induced by the presence of a tumor elsewhere in the organ. PloS One 10, e0130076 (2015).","journal-title":"PloS One"},{"key":"15105_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/pros.23749","volume":"79","author":"H Adamo","year":"2019","unstructured":"Adamo, H. et al. Prostate cancer induces c\/ebp$$\\beta$$ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome. Prostate 79, 435\u2013445 (2019).","journal-title":"Prostate"},{"key":"15105_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176679","volume":"12","author":"K Str\u00f6mvall","year":"2017","unstructured":"Str\u00f6mvall, K., Thysell, E., Halin Bergstr\u00f6m, S. & Bergh, A. Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis. PLoS One 12, e0176679 (2017).","journal-title":"PLoS One"},{"key":"15105_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/pros.23466","volume":"78","author":"SH Bergstr\u00f6m","year":"2018","unstructured":"Bergstr\u00f6m, S. H., J\u00e4remo, H., Nilsson, M., Adamo, H. H. & Bergh, A. Prostate tumors downregulate microseminoprotein-beta (msmb) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness. Prostate 78, 257\u2013265 (2018).","journal-title":"Prostate"},{"key":"15105_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/path.5604","volume":"253","author":"S Halin","year":"2021","unstructured":"Halin, S. et al. High-grade tumours promote growth of other less-malignant tumours in the same prostate. J. Pathol. 253, 396\u2013403 (2021).","journal-title":"J. Pathol."},{"key":"15105_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pros.20927","volume":"69","author":"P Wikstr\u00f6m","year":"2009","unstructured":"Wikstr\u00f6m, P., Marusic, J., Stattin, P. & Bergh, A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69, 799\u2013809 (2009).","journal-title":"Prostate"},{"key":"15105_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2353\/ajpath.2010.100070","volume":"177","author":"A Johansson","year":"2010","unstructured":"Johansson, A. et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am. J. Pathol. 177, 1031\u20131041 (2010).","journal-title":"Am. J. Pathol."},{"key":"15105_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/1078-0432.CCR-09-0103","volume":"16","author":"P Hammarsten","year":"2010","unstructured":"Hammarsten, P. et al. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin. Cancer Res. 16, 1245\u20131255 (2010).","journal-title":"Clin. Cancer Res."},{"key":"15105_CR21","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.ajpath.2011.06.005","volume":"179","author":"A Josefsson","year":"2011","unstructured":"Josefsson, A. et al. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. Am. J. Pathol. 179, 1961\u20131968 (2011).","journal-title":"Am. J. Pathol."},{"key":"15105_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/00365599.2012.669791","volume":"46","author":"A Josefsson","year":"2012","unstructured":"Josefsson, A. et al. Low endoglin vascular density and ki67 index in gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand. J. Urol. Nephrol. 46, 247\u2013257 (2012).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"15105_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41551-020-00682-w","volume":"5","author":"MY Lu","year":"2021","unstructured":"Lu, M. Y. et al. Data-efficient and weakly supervised computational pathology on whole-slide images. Nat. Biomed. Eng. 5, 555\u2013570 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"15105_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","volume":"77","author":"JJ Tosoian","year":"2020","unstructured":"Tosoian, J. J. et al. Active surveillance of grade group 1 prostate cancer: Long-term outcomes from a large prospective cohort. Eur. Urol. 77, 675\u2013682 (2020).","journal-title":"Eur. Urol."},{"key":"15105_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1145\/965139.807361","volume":"12","author":"AR Smith","year":"1978","unstructured":"Smith, A. R. Color gamut transform pairs. ACM Siggraph Computer Graph. 12, 12\u201319 (1978).","journal-title":"ACM Siggraph Computer Graph."},{"key":"15105_CR26","first-page":"23","volume":"11","author":"N Otsu","year":"1975","unstructured":"Otsu, N. et al. A threshold selection method from gray-level histograms. Automatica 11, 23\u201327 (1975).","journal-title":"Automatica"},{"key":"15105_CR27","volume":"7","author":"O Ciga","year":"2022","unstructured":"Ciga, O., Xu, T. & Martel, A. L. Self supervised contrastive learning for digital histopathology. Machine Learn. Appl. 7, 100198 (2022).","journal-title":"Machine Learn. Appl."},{"key":"15105_CR28","doi-asserted-by":"crossref","unstructured":"McInnes, L., Healy, J. & Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:1802.03426 (2018).","DOI":"10.21105\/joss.00861"},{"key":"15105_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41597-025-04758-7","volume":"12","author":"E Chelebian","year":"2025","unstructured":"Chelebian, E. et al. A clinical prostate biopsy dataset with undetected cancer. Sci. Data 12, 423 (2025).","journal-title":"Sci. Data"},{"key":"15105_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1470-2045(19)30738-7","volume":"21","author":"P Str\u00f6m","year":"2020","unstructured":"Str\u00f6m, P. et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: A population-based, diagnostic study. Lancet Oncol. 21, 222\u2013232 (2020).","journal-title":"Lancet Oncol."},{"key":"15105_CR31","doi-asserted-by":"crossref","unstructured":"Liu, B. et al. Using deep learning to detect patients at risk for prostate cancer despite benign biopsies. Iscience. 25 (2022).","DOI":"10.1016\/j.isci.2022.104663"},{"key":"15105_CR32","doi-asserted-by":"crossref","unstructured":"Bouzid, K. et al. Enabling large-scale screening of barrett\u2019s esophagus using weakly supervised deep learning in histopathology. medRxiv 2023\u201308 (2023).","DOI":"10.1101\/2023.08.21.23294360"},{"key":"15105_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-5-45","volume":"5","author":"UR Chandran","year":"2005","unstructured":"Chandran, U. R. et al. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5, 1\u201311 (2005).","journal-title":"BMC Cancer"},{"key":"15105_CR34","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1158\/1078-0432.CCR-10-0272","volume":"16","author":"MC Risk","year":"2010","unstructured":"Risk, M. C. et al. Differential gene expression in benign prostate epithelium of men with and without prostate cancer: Evidence for a prostate cancer field effect. Clin. Cancer Res. 16, 5414\u20135423 (2010).","journal-title":"Clin. Cancer Res."},{"key":"15105_CR35","doi-asserted-by":"crossref","unstructured":"Stenman, K. et al. H hrmas nmr derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples. Biomarker Insights. 6, BMI\u2013S6794 (2011).","DOI":"10.4137\/BMI.S6794"},{"key":"15105_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4038","volume":"32","author":"SS Dinges","year":"2019","unstructured":"Dinges, S. S. et al. Metabolomic prostate cancer fields in hrmas mrs-profiled histologically benign tissue vary with cancer status and distance from cancer. NMR Biomed. 32, e4038 (2019).","journal-title":"NMR Biomed."},{"key":"15105_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pros.23191","volume":"76","author":"L Van Neste","year":"2016","unstructured":"Van Neste, L. et al. Risk score predicts high-grade prostate cancer in dna-methylation positive, histopathologically negative biopsies. Prostate 76, 1078\u20131087 (2016).","journal-title":"Prostate"},{"key":"15105_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.juro.2014.04.013","volume":"192","author":"AW Partin","year":"2014","unstructured":"Partin, A. W. et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J. Urol. 192, 1081\u20131087 (2014).","journal-title":"J. Urol."},{"key":"15105_CR39","doi-asserted-by":"crossref","unstructured":"Trujillo, K.\u00a0A., Jones, A.\u00a0C., Griffith, J.\u00a0K., Bisoffi, M. et al. Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer. 2012 (2012).","DOI":"10.1155\/2012\/302894"},{"key":"15105_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187086","volume":"12","author":"K Str\u00f6mvall","year":"2017","unstructured":"Str\u00f6mvall, K., Lundholm, M., Thysell, E., Bergh, A. & Halin Bergstr\u00f6m, S. Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth. Plos One 12, e0187086 (2017).","journal-title":"Plos One"},{"key":"15105_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2020.04.029","volume":"78","author":"JM Norris","year":"2020","unstructured":"Norris, J. M. et al. What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the promis cohort. Eur. Urol. 78, 163\u2013170 (2020).","journal-title":"Eur. Urol."},{"key":"15105_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","volume":"48","author":"L Evangelista","year":"2021","unstructured":"Evangelista, L. et al. Pet\/mri in prostate cancer: A systematic review and meta-analysis. Eur. J. Nuclear Med. Mol. Imaging 48, 859\u2013873 (2021).","journal-title":"Eur. J. Nuclear Med. Mol. Imaging"},{"key":"15105_CR43","doi-asserted-by":"publisher","first-page":"R187","DOI":"10.1530\/ERC-12-0085","volume":"19","author":"DA Barron","year":"2012","unstructured":"Barron, D. A. & Rowley, D. R. The reactive stroma microenvironment and prostate cancer progression. Endocr.-Related Cancer 19, R187\u2013R204 (2012).","journal-title":"Endocr.-Related Cancer"},{"key":"15105_CR44","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/sj.bjc.6605815","volume":"103","author":"A Gupta","year":"2010","unstructured":"Gupta, A. et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European randomized study of prostate cancer screening in Rotterdam, Netherlands. Br. J. Cancer 103, 708\u2013714 (2010).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15105-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15105-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15105-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:22:10Z","timestamp":1757413330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15105-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15105"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15105-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.W. is on the advisory board of Navinci Diagnostics, Sweden. The rest of the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30770"}}